Hypoxia‐inducible factor 2α inhibition in renal cell carcinoma: From von Hippel–Lindau biology to targeted therapeutics
Cancer · 15.11.2026 · 132 (22)
DOI: 10.1002/cncr.70682 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 13.11.2026. Verfasst von Yu-Wei Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University of California, San Diego, Moores Cancer Center, San Diego, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Basic Helix-Loop-Helix Proteins, Kidney Neoplasms, Von Hippel-Lindau Tumor Suppressor Protein. Die Arbeit nennt 54 Literaturangaben.
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) is characterized by the dysregulation of cellular oxygen sensing resulting from inactivation of the von Hippel–Lindau (VHL) tumor‐suppressor gene. Loss of VHL function leads to constitutive activation of hypoxia‐inducible factor (HIF) signaling, with HIF‐2α emerging as the dominant oncogenic driver of angiogenesis, metabolic reprogramming, tumor growth, and metastasis. The discovery of a druggable cavity within the HIF‐2α PAS‐B domain transformed a previously undruggable transcription factor into a therapeutic target and enabled the development of selective HIF‐2α inhibitors. Belzutifan, the first approved HIF‐2α inhibitor, has demonstrated meaningful clinical activity in VHL disease–associated neoplasms and advanced ccRCC, validating direct inhibition of the VHL–HIF pathway as a therapeutic strategy. More recently, belzutifan in combination with pembrolizumab was approved as adjuvant therapy for patients with resected ccRCC. Separately, the development of next‐generation HIF‐2α inhibitors, HIF‐1β (also known as aryl hydrocarbon receptor nuclear translocator)–targeted degraders, and novel combination strategies, including those incorporating vascular endothelial growth factor–targeted therapies, continues to broaden the therapeutic potential of HIF‐directed treatment. In this review, the authors summarize the biologic basis of the VHL–HIF axis, the development of HIF‐targeted therapies, key clinical data supporting their use in renal cell carcinoma, and future directions for this rapidly evolving therapeutic class.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, University of California, San Diego, Moores Cancer Center, San Diego, California, USA.
- University of California, San Diego School of Medicine, San Diego, California, USA.
ORCID-Profile: Rana R McKay
Zitieren
APA
Chen, Y. W., Sano, F., & McKay, R. R. (2026). Hypoxia‐inducible factor 2α inhibition in renal cell carcinoma: From von Hippel–Lindau biology to targeted therapeutics. Cancer, 132(22). https://doi.org/10.1002/cncr.70682
Vancouver
Chen YW, Sano F, McKay RR. Hypoxia‐inducible factor 2α inhibition in renal cell carcinoma: From von Hippel–Lindau biology to targeted therapeutics. Cancer. 2026;132(22). doi:10.1002/cncr.70682
BibTeX
@article{Chen2026,
author = {Chen, Yu-Wei and Sano, Fumika and McKay, Rana R},
title = {Hypoxia‐inducible factor 2α inhibition in renal cell carcinoma: From von Hippel–Lindau biology to targeted therapeutics},
journal = {Cancer},
year = {2026},
volume = {132},
number = {22},
doi = {10.1002/cncr.70682}
}
EUVIMED